^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    dexamethasone sodium phosphate (AVM0703)

    i
    Other names: AVM0703, AVM 0703, AVM-0703, PlenaStem, AugmenStem
    Associations

    News

    Trials
    Company:
    AVM Biotechnology
    Drug class:
    γδ TCR modulator, GCR antagonist, NKT cell stimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, AVM Biotechnology Inc | Trial completion date: Mar 2025 --> Mar 2032 | Trial primary completion date: Dec 2024 --> Dec 2031
    Trial completion date • Trial primary completion date
    |
    dexamethasone sodium phosphate (AVM0703)
    2ms
    The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies (clinicaltrials.gov)
    P1/2, N=144, Recruiting, AVM Biotechnology Inc | Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    |
    dexamethasone sodium phosphate (AVM0703)
    over2years
    Induction and Mobilization of Endogenous Bispecific Gamma Delta TCR+ Invariant TCR+ Natural Killer T Cell-Like Cells in Non-Hodgkin's Lymphoma and Solid Tumor Patients (IO-SUMMIT EUROPE 2023)
    Preclinically, activity has been demonstrated against autoreactive T/B cells, immune-resistant lymphoma, xenografted human T-ALL, melanoma, and multiple myeloma. AVM0703 is also effective as neoadjuvant before chemoimmunotherapy or cell transplant.
    Clinical
    |
    dexamethasone sodium phosphate (AVM0703)